GeniPhys Receives FDA 510(k) Clearance for First-in-Class Self-Assembling Collagen Scaffold for Wound Care
核心洞察
GeniPhys (搜索) has received FDA 510(k) clearance for Collymer Self-Assembling Scaffold (SAS), a novel two-part flowable wound management device that forms scaffolds through in situ collagen self-assembly.
The device is indicated for managing diverse wound types including partial- and full-thickness wounds (搜索), skin ulcers, surgical wounds, and trauma wounds, addressing critical unmet needs for millions of patients.
The technology, developed at Purdue University and backed by over a decade of peer-reviewed research, overcomes limitations of conventional implantable materials by adapting to complex wound geometries.
GeniPhys (搜索), a medtech innovator specializing in next-generation regenerative collagen polymeric biomaterials, has achieved a significant regulatory milestone with FDA 510(k) clearance for its flagship product, Collymer Self-Assembling Scaffold (SAS). This first-in-class approval paves the way for commercial launch and introduces a novel solution in the wound care market.
"This is a momentous event for GeniPhys (搜索) and I'm incredibly proud of our team effort in reaching this goal," said Andy Eibling, president and CEO of GeniPhys. "Achieving this objective supports our current fundraising efforts that will enable commercialization of Collymer SAS (搜索)."
Novel Self-Assembly Technology
Collymer SAS (搜索) represents a breakthrough in wound management technology, featuring a two-part, flowable device composed of a highly purified collagen solution and a self-assembly reagent. When combined, the solutions initiate in situ collagen self-assembly, forming a scaffold that supports cellular infiltration and vascularization.
"It's deeply rewarding to see this technology move closer to clinical use, where it has the potential to address critical unmet needs for millions of patients," said Sherry Harbin, founder and chief technology officer of GeniPhys (搜索). "Our collagen polymer platform was developed to overcome limitations associated with conventional implantable materials, and its ability to adapt to complex wound geometries marks a meaningful advancement for both patients and clinicians."
Broad Clinical Applications
The FDA clearance covers an extensive range of wound types, demonstrating the versatility of the Collymer platform. Collymer SAS (搜索) is indicated for the management of partial- and full-thickness wounds (搜索), skin ulcers (pressure, venous, diabetic and chronic vascular), tunneled or undermined wounds, surgical wounds (donor sites, grafts, post-Mohs, post-laser, podiatric and wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns (搜索) and skin tears), and draining wounds.
Strong Intellectual Property Foundation
The Collymer platform anchors a growing intellectual property portfolio with nearly 20 issued or pending patents. Harbin, a professor of biomedical engineering and courtesy professor of basic medical sciences at Purdue University, led the development of the Collymer platform in collaboration with her research team. The technology is exclusively licensed to GeniPhys (搜索) through the Purdue Innovates Office of Technology Commercialization (搜索) and is backed by more than a decade of peer-reviewed research that documents the self-assembling behavior and distinctive "regenerative remodeling" of the collagen material in various preclinical models.
Commercialization Strategy
GeniPhys (搜索) is actively raising capital to support commercialization efforts, including final manufacturing qualification, process validation and scale-up through in-house and contract manufacturing. The company, founded in 2014, is also pursuing strategic partnerships to accelerate product launch and adoption in the advanced wound care market.
The company's vision extends beyond the current product, aiming to become a global manufacturer and supplier of Collymer biopolymer as well as next-generation implantable collagen polymeric materials for improved tissue restoration outcomes.